Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Valproate efficacy in major depressive disorder

Feb. 13, 1997

Encouraging phase IIb results for antiparkinsonian patch

Feb. 13, 1997

Alza obtains rights to opioid analgesic and licenses the product to Knoll

Feb. 13, 1997

Potential cognition-enhancing agent described by Rotta

Feb. 12, 1997

Servier describes 5-HT3 agonist with additionial antagonist-like properties

Feb. 12, 1997

Cephalon and Chiron seek FDA approval for rhIGF-1

Feb. 12, 1997

Neurotrophic rotamase inhibitors described by Guilford

Feb. 12, 1997

Anticonvulsants with favorable protection indices reported by Canadian researchers

Feb. 12, 1997

Positive phase III trials results for citicoline

Feb. 11, 1997

Essential fatty acids in schizophrenia

Feb. 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.